Platinum drugs are widely used in the treatment of various solid tumors, but their resistance to platinum is the most significant obstacle to successful treatment. Copper transporter 1 (CTR1) is the specific transporter for copper, and it mainly locates at the plasma membrane and plays a role in pumping copper into the cell. CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. The expression, polymorphism, and degradation of CTR1 affect platinum resistance in tumors. Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.
Antineoplastic Agents ; therapeutic use ; Cation Transport Proteins ; genetics ; metabolism ; Cisplatin ; therapeutic use ; Copper ; Copper Transporter 1 ; Drug Resistance, Neoplasm ; genetics ; Platinum ; therapeutic use ; Research ; trends